The first report of ocular manifestation among COVID‐19 patients was provided by a member of the National Expert Panel on Pneumonia, who was infected during his inspection in Wuhan, despite wearing an N95 mask.
1 This expert did not wear an eye protection or face shield, and several days before developing pneumonia, he reported redness of his eyes, which led to the suggestion that unprotected exposure of the eyes might have allowed the virus to infect the body.
1 Isolated case studies have described the virus persistence in the ocular surface past the initial infection phase. Chen et al.
2 indicated the development of bilateral acute follicular conjunctivitis at day 13 of illness in a 30-year-old COVID‐19 patient, with SARS‐CoV‐2 RNA being present in the conjunctival specimens between 9 and 18 days of disease. Prolonged presence of viral RNA has also been described in a clinical case report of a Chinese COVID‐19–positive patient who traveled from China to Italy and presented with bilateral conjunctivitis at day 1 of hospitalization. Viral RNA was detected by reverse transcriptase polymerase chain reaction (RT‐PCR) on the conjunctival swab samples from day 3 to day 21 at lower Ct values than nasal swabs. Although no viral RNA was detected between days 22 and 26 in both nasal and conjunctival swabs, low expression was detected in conjunctival swabs at day 27, which indicates a sustained infection, also corroborated by the successful viral inoculation in Vero E6 cells.
3 To ascertain the impacts of COVID‐19 on the ocular surface, a prospective observational study assessed 38 confirmed COVID‐19 patients and 31 healthy controls.
4 Although no significant differences were observed regarding age and gender between the two groups, conjunctival impression cytology revealed decreased density and enlargement of goblet cells, squamous changes, and increased presence of neutrophils in the COVID‐19 patients. Together these data demonstrate that SARS‐CoV‐2 infection of the ocular surface is observed at low frequency.
5 Possibly corneal and conjunctival epithelial cells are protected by the tear film and the fast drainage (approximately every five minutes) that might provide a barrier for infection of the underlying epithelia. It has been postulated that the tear film, particularly the superficial lipid layer, may act as a barrier to prevent SARS‐CoV‐2 binding to the corneal/conjunctival epithelia entry receptors. Furthermore, the tear flow may provide an “ocular surface wash-out” effect, preventing prolonged persistence of virus on the ocular surface. Nonetheless, if the virus makes its way to the ocular surface epithelium, through the tear film, tear flow and drainage may facilitate a second route of infection binding to receptors in and beyond the nasolacrimal system.
6